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Meta-Analysis and Systematic Review
Association of interleukin
10 rs1800896 polymorphism
with susceptibility to breast
cancer: a meta-analysis
ZiYin Zhu1, Ji-Bin Liu2, Xi Liu1 and
LinXue Qian1
Abstract
Objective: To evaluate the correlation between interleukin 10 (IL-10) 1082A/G polymorphism
(rs1800896) and breast cancers by performing a meta-analysis.
Methods: The Embase and Medline databases were searched through 1 September 2018 to
identify qualified articles. Odds ratios (OR) and corresponding 95% confidence intervals (CIs)
were applied to evaluate associations.
Results: In total, 14 case-control studies, including 5320 cases and 5727 controls, were analyzed.
We detected significant associations between the IL10 1082 G/G genotype and risk of breast
cancer (AAþAG vs. GG: OR¼ 0.88, 95% CI¼ 0.80–0.97). Subgroup analyses confirmed a sig-
nificant association in Caucasian populations (OR¼ 0.89, 95% CI¼ 0.80–0.99), in population-
based case-control studies (OR¼ 0.87, 95% CI¼ 0.78–0.96), and in studies with 500 subjects
(OR¼ 0.88, 95% CI¼ 0.79–0.99) under the recessive model (AAþAG vs. GG). No associations
were found in Asian populations.
Conclusions: The IL10 1082A/G polymorphism is associated with an increased risk of breast
cancer. The association between IL10 1082 G/G genotype and increased risk of breast cancer is
more significant in Caucasians, in population-based studies, and in larger studies.
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Introduction
Breast cancer is regarded as the most
common cancer among women, and about
6.6% of cases are diagnosed among women
40 years old or younger.1 Breast cancer
accounts for 40% of all types of cancers
diagnosed in women and is the third-
leading cause among all cancer deaths in
Western countries,2 although the death
rate has decreased in most developed coun-
tries with the help of improved treatments
and earlier diagnosis.
Over the last few years, several mecha-
nisms have been postulated regarding the
etiology and progression of breast cancer.3
It has been shown that chronic inflammato-
ry responses play essential roles in develop-
ment of all kinds of cancers. Inflammatory
cells can regulate the tumor microenviron-
ment and are clearly implicated in tumor
development by facilitating proliferation,
migration, and survival.4,5 Several cyto-
kines, including interferon-a, interleukin
(IL)-2, IL-6, IL-8, IL-10, and tumor necro-
sis factor-a, have essential and coordinated
functions in breast carcinogenesis.6,7 As a
multifunctional anti-inflammatory cyto-
kine, IL-10 represses the inflammatory
response to tumor microenvironments. It
is usually secreted by immune cells, such
as monocytes, T cells, macrophages (if stim-
ulated appropriately), certain subsets of
dendritic cells, and B cells.8,9
The human IL10 gene, containing five
exons, is located on chromosome 1q32.1.
The promoter region contains at least 40
polymorphic sites, and these sites may
affect gene transcription.10–12 An A-to-G
single base pair substitution designated
rs1800896 (1082A/G) has been found in
the IL10 gene promoter region, located
1082 bp (upstream) of the transcriptional
start site. The IL10 1082A/G polymor-
phism is closely connected to IL-10 expres-
sion.13–15 However, there is currently no
agreement on whether an association
exists between breast cancer and the
1082A/G polymorphism. This meta-
analysis was designed to clarify whether
rs1800896 (1082A/G) is associated with
breast cancer risk through an investigative
analysis of the published literature.
Methods
Identification and selection of studies
Relevant studies from Medline (since
1 January 1966) and Embase (since
1 January 1974) through 1 September
2018 were systematically searched (by
Z. Zhu and J.-B. Liu). Eligible studies
were identified using the keywords
“IL-10”, “Interleukin-10”, “-1082 A/G”,
“rs1800896”, “polymorphism”, “genotype”,
“mutation” “variant”, and “breast cancer”.
Then, all references of retrieved studies, clin-
ical trials, review articles, and previous meta-
analyses were examined to identify relevant
studies that may have been missed in the
electronic database searches. The complete
search strategy is shown in the supplemen-
tary data (Supplemental Document 1).
Eligibility criteria
Eligible studies had to meet the following
criteria: (1) evaluated the connection
between IL10 1082A/G polymorphism
and breast cancer risk; (2) characterized by
a case-control or cohort design; (3) provided
enough data for calculation of odds ratios
(ORs) and their 95% confidence intervals
(95% CIs). If multiple studies presented the
same data, only the study with the latest
data, the largest sample size, or the complet-
ed study was included. The exclusion criteria
were (1) review article, case report, or an
abstract only; (2) studies without a case-
control population or not a cohort design;
(3) lack of essential data; (4) studies without
a control group of healthy individuals; and
(5) duplicates of previous prior articles.
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Data collection and quality evaluation
From the eligible studies, two authors
(Z. Zhu and J.-B. Liu) independently col-
lected relevant data, if available: first
author, publication year, country of
origin, ethnicity of patients, total numbers
of cases and controls, genotype frequencies,
genotyping technique, minor allele fre-
quency, and P-value for Hardy–Weinberg
equilibrium (HWE). For any disagree-
ments between the two data sets, consen-
sus was reached through discussion or
following assessment by a third author. In
control groups, confirmation of HWE was
applied to assess the quality of study: high-
quality studies have HWE confirmation in
controls whereas low-quality ones do not.
Quality assessment of included studies
The Newcastle–Ottawa Scale (NOS) of
case-control studies was used to determine
the methodological quality for each includ-
ed study. The NOS contains eight elements,
as shown in Supplemental Table 1.
Statistics
The correlation between the IL10 1082A/
G polymorphism (rs1800896) and breast
cancer risk was assessed by crude ORs
with 95% CIs. A summary estimate of the
OR was obtained by calculating the weight-
ed average of the ORs for each study. The
Z-test was carried out to assess whether the
pooled OR was statistically significant. This
meta-analysis was based on the allele model
(A vs. G), the dominant model (AA vs.
AGþGG), recessive model (AAþAG vs.
GG), co-dominant heterozygote model
(AA vs. AG), co-dominant homozygote
model (AA vs. GG), and the over-
dominant model (AAþGG vs. AG). In
the meta-analysis, heterogeneity between
studies was assessed using the I2 value and
the Q-statistic. The I2 value describes the
degree of heterogeneity between studies.
A value of 0 to 25% indicates no detected
heterogeneity, 25% to 50% indicates lowly
increased heterogeneity, 50% to 75% mod-
erately increased heterogeneity, and 75% to
100% highly increased heterogeneity.16,17
For the Q-statistic, a P-value>0.10 indicates
a lack of heterogeneity between studies. An
estimate of pooled OR was determined by
the fixed-effects model (Mantel–Haenszel
method).18 In addition, the random-effects
model (DerSimonian and Laird method)
was used.19 Subgroup analyses, HWE
status, and meta-regression were performed
to adjust the heterogeneity between studies.
In controls, a departure from HWE was
evaluated using the v2 test. A P-value
<0.05 represents statistical significance.
Analyses of one-way sensitivity were made
to evaluate the stability of results. That is,
with each calculation, one study was
removed from the meta-analysis so that the
effect of an individual dataset on the pooled
OR could be determined. Any potential pub-
lication bias was identified by using funnel
plots and Egger’s linear regression test.20,21
To guarantee the accuracy and reliability of
the results, data were entered independently
by two researchers and consensus was
reached. Comprehensive Meta-Analysis
software version 2.20 (Stata Corp., College
Station, TX, USA) was applied to perform
all data analyses. All P-values were two-
sided and considered significant if P< 0.05.
Patient and public involvement
There was no direct patient or public
involvement in current study and therefore
ethical approval and patient consent were
not required.
Results
Study characteristics
As shown in Figure 1, our search criteria
returned 253 published articles. Fourteen
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studies,22–35 containing 5320 breast cancer-
related cases and 5727 control cases, were
identified. A meta-analysis database was
established based on the information
extracted from the 14 selected studies:
8 (57%) focused on Caucasian populations,
4 (29%) on Asian populations, 1 (7%) on
African populations, and 1 (7%) had a
mixed population.
All 14 studies included cases and controls.
Nine (64%) studies were population-based
and 5 (36%) were hospital-based. They used
a range of gene detection methods: PCR,
restriction fragment length polymorphism
(RFLP)-PCR, amplification-refractory
mutation system (ARMS)-PCR, allele-
specific (AS)-PCR), and sequence-specific
amplification (SSP)-PCR. Sample size
varied greatly across studies, from a mini-
mum of 62 to a maximum of 4483. For
controls, all genotype distributions were
consistent with HWE for the IL10 1082
A/G polymorphism. Details are shown in
Table 1.
Figure 1. PRISMA flow chart depicting the procedure for the identification of studies.
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Overall data
Fourteen separate studies, including 5320
breast cancer cases and 5727 control
cases, were identified to explore associa-
tions. The key findings are demonstrated
in Table 2. There was an overall significant
association as determined by both the
recessive model (AAþAG vs. GG:
OR¼ 0.88, 95% CI¼ 0.80–0.97; P¼ 0.01;
Figure 2a) and the co-dominant homozy-
gotes model (AA vs. GG: OR¼ 0.88, 95%
CI¼ 0.78–0.98; P¼ 0.03; Figure 2b). The
results showed an association of IL10
1082 G/G genotype with increased
breast cancer risk. However, no obvious
association was found between the frequen-
cy of the IL10 1082 A/G polymorphism
and breast cancer as determined by the
allele model (A vs. G: OR¼ 0.97, 95%
CI¼ 0.87–1.08), the dominant model (AA
vs. AGþGG: OR¼ 1.02, 95% CI¼ 0.85–
1.21), the co-dominant heterozygotes model
(AA vs. GA: OR¼ 1.09, 95% CI¼ 0.9–
1.33), or the over-dominant model
(AAþGG vs. AG: OR¼ 1.13, 95%
CI¼ 0.97–1.32).
Subgroup analysis by ethnicity
After stratifying the data for ethnicity, we
observed that in Caucasian populations,
based on eight studies (4348 patients and
4730 control cases), an obvious association
was found between IL10 1082 G/G geno-
type and increased risk of breast cancer in
the recessive model (AAþAG vs. GG:
OR¼ 0.89, 95% CI¼ 0.80–0.99; P¼ 0.04;
Table 2 and Figure 3a) and the co-
dominant homozygotes model (AA vs.
GG: OR¼ 0.88, 95% CI¼ 0.78–1.00;
P¼ 0.05; Table 2 and Figure 3b).
However, in Asian groups, there was no
association between IL10 1082 G/G poly-
morphism and increased breast cancer risk
in any model (Table 2, Figure 3a and 3b). T
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Subgroup analysis by study design
In the study design subgroups, pooled anal-
yses of population-based case-control stud-
ies showed a close association of IL10
1082 G/G genotype with an increase in
breast cancer risk based on the recessive
model (AAþAG vs. GG: OR¼ 0.87, 95%
CI¼ 0.78–0.96; P¼ 0.01; Table 2 and
Figure 2. Forest plot of breast cancer risk in all studies (overall) associated with the IL10 1082A/G
(rs1800896) polymorphism under (a) the recessive model (AAþAG vs. GG), and (b) the co-dominant
homozygotes model (AA vs. GG). IL10, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence
interval.
Figure 3. Forest plot of breast cancer risk in ethnicity subgroups (Caucasian vs. Asian) associated with the
IL10 1082A/G (rs1800896) polymorphism under (a) the recessive model (AAþAG vs. GG), and (b) the
co-dominant homozygotes model (AA vs. GG). IL10, interleukin-10 gene, OR, odds ratio; 95% CI, 95%
confidence interval.
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Figure 4a) and the co-dominant homozy-
gotes model (AA vs. GG: OR¼ 0.87, 95%
CI¼ 0.77–0.97; P¼ 0.02; Table 2 and
Figure 4b). None of the ORs in
hospital-based case-control studies were
statistically significant (Table 2 and
Figure 4a and 4b).
Subgroup analysis by sample size
We then stratified analyses by sample size,
with a cutoff of 500 subjects (i.e., sample
size <500 vs. 500).36 A higher risk
of breast cancer was observed in studies
with 500 subjects under the recessive
model (AAþAG vs. GG: OR¼ 0.88,
95% CI¼ 0.79–0.99; P¼ 0.03; Table 2
and Figure 5a) and the co-dominant
homozygotes model (AA vs. GG:
OR¼ 0.86, 95% CI¼ 0.76–0.98; P¼ 0.03;
Table 2 and Figure 5b). In the subgroup
with sample size <500, there were no signif-
icant changes in ORs in any of the genetic
models.
Publication bias
To evaluate the potential publication bias of
these studies, Egger’s test and Begg’s funnel
plots were used. For the recessive (AAþAG
vs. GG) and co-dominant homozygote (AA
vs. GG) models, the findings from Begg’s
funnel plots showed no obvious asymmetry
(Figure 6a and 6b). The results of Egger’s
tests suggested no evidence of publication
bias for the recessive (AAþAG vs. GG)
and co-dominant homozygote (AA vs.
GG) models (t¼ 0.50, P¼ 0.627; t¼ 0.85,
P¼ 0.411, respectively).
Discussion
Main findings
The findings from our meta-analysis of 14
studies, which involved 5320 cases and 5727
controls, indicated a significant correlation
between the IL10 1082 G/G genotype and
an increase in breast cancer risk. The signifi-
cant association was confirmed in further
Figure 4. Forest plot of breast cancer risk in control source subgroups (hospital-based controls vs.
population-based controls) associated with the IL10 1082A/G (rs1800896) polymorphism under (a) the
recessive model (AAþAG vs. GG), and (b) the co-dominant homozygotes model (AA vs. GG). IL10,
interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.
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analyses among the Caucasian subgroup, the
population-based case-control subgroup,
and the subgroup of sample size 500.
Tumors are closely associated with
chronic inflammation.37 The multifunc-
tional cytokine IL-10 is secreted by
T helper (Th)2 cells and has both immuno-
suppressive and anti-angiogenic functions,
suggesting that IL-10 is involved in tumor
development and progression. Some in vitro
studies have shown that IL-10 promotes the
proliferation and migration of MCF-7
Figure 5. Forest plot of breast cancer risk in sample size subgroups (<500 vs. 500 samples) associated
with the IL10 1082A/G (rs1800896) polymorphism under (a) the recessive model (AAþAG vs. GG), and
(b) the co-dominant homozygotes model (AA vs. GG).
IL10, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.
Figure 6. Begg’s funnel plot of the publication bias test under (a) the recessive model (AA þ AG vs. GG),
and (b) the co-dominant homozygotes model (AA vs. GG). Each point represents a separate study for the
indicated association.
OR, odds ratio.
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breast cancer cells.38 Low expression of
IL10 in tumor cells increases the risk of
poor prognosis in breast cancer.39 Studies
have also shown that IL10 1082A/G poly-
morphisms (in the promotor region of
IL10) affect IL-10 expression,40 and that
the 1082 G allele is associated with
poorly differentiated adenocarcinoma of
breast cancer.41
Prior studies have explored the relation-
ship between the IL10 1082A/G polymor-
phism and breast cancer risk but most failed
to find a correlation. Some studies report
that the AA genotype of the polymorphism
is correlated with an increase in breast
cancer risk,22,33 which is inconsistent with
the present study’s findings. However, the
limitations of those studies should be men-
tioned. Both included small sample sizes and
only reported GG, GA, and AA instead of
combined genotypes GGþGA and
GAþAA. Our paper represents the most
comprehensive meta-analysis on this issue,
and it expands on prior meta-analyses by
including a larger sample size as well as sub-
group analyses. In particular, we believe that
the present research is the most accurate
meta-analysis to date because of the inclu-
sion of a subgroup for study quality as deter-
mined by HWE status.
The incidence of gene polymorphisms
can vary substantially across racial or
ethnic populations with different genetic
backgrounds, which influences measures of
association between polymorphisms and
cancer susceptibility. Subgroup analyses
by ethnicity showed an obvious association
between GG genotypes and an increased
risk of breast cancer in Caucasian but not
Asian populations. These finding suggests
that genetic diversity or natural selection
is occurring at different rates in different
ethnicities. The sample size of the African
population was too small to draw conclu-
sions on associations.
Subgroup analyses indicate that differen-
ces in either study design or the number of
subjects affect the calculated risk associa-
tions. Significant associations between GG
genotypes and an increased risk of breast
cancer were identified in the population-
based case-control subgroup and the large
sample size (500) subgroup, but not in the
hospital-based case-control subgroup or the
small sample size (<500) subgroup.
Therefore, more rigorous and uniform stud-
ies should be conducted to accurately define
these associations.
Strengths and limitations
This study has several advantages. First, it is
a comprehensive and largemeta-analysis that
evaluates the association of IL10 1082A/G
polymorphism with breast cancer risk, which
makes this study more powerful than prior
analyses. Second, meta-analysis results
showed that the GG genotype of the IL10
1082A/G polymorphism was associated
with an increased risk of breast cancer.
Finally, subgroup stratifications were
designed to exclude the influence of different
factors, making the statistical outcomesmore
precise and reliable.
There are also several study limitations.
First, the raw data from the literature were
limited and some relevant studies were
excluded from the final analyses because
of inclusion criteria, as shown in Figure 1.
In three relevant articles, we could not
extract the data we wanted.42–44 Second,
the sample sizes in some subgroups were
small. Third, there were inconsistencies in
the types of controls across studies.
Control group samples included those
from population-based healthy individuals
and from hospitalized patients without
cancer. Thus, samples from control groups
may not represent the potential source pop-
ulation, especially in cases where the poly-
morphism affects the risk of other diseases.
Finally, this study was based on unadjusted
data. A more accurate study could be
10 Journal of International Medical Research
performed if data from individuals were
available.
Despite the above limitations, our meta-
analysis suggested that the IL10 1082A/G
polymorphism (rs1800896) is closely
associated with breast cancer risk. Future
investigations to estimate the effects of
gene–gene and gene–environment interac-
tions on breast cancer are necessary for a
better understanding of these interactions.
Stratification by ethnicity, cancer type,
study design, and sample size should be
standardized in future studies on the genet-
ics of breast cancer, which should also
consider correlations between the IL10
1082A/G polymorphism and breast
cancer risk.
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Search Strategies
Medline by OVID
1. “interleukin-10” [MeSH Terms]
2. “interleukin-10” [All Fields]
3. “IL 10 ”[All Fields]
4. 1 OR 2 OR 3
5. “breast” [All Fields]
6. “neoplasms” [MeSH Terms]
7. “neoplasms” [All Fields]
8. “cancer” [All Fields]
9. 6 OR 7 OR 8
10. 5 AND 9
11. Polymorphism
12. 4 AND 10 AND 11
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Embase by OVID
1. “interleukin-10” [MeSH Terms]
2. “interleukin-10” [All Fields]
3. “IL 10” [All Fields]
4. 1 OR 2 OR 3
5. “breast” [All Fields]
6. “neoplasms” [MeSH Terms]
7. “cancer” [All Fields]
8. 6 OR 7
9. 5 AND 8
10. Polymorphism
11. 4 AND 8 AND 10
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